# Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/assessing-the-effects-of-food-on-drugs-in-inds-and-ndas-clinical-pharmacology-considerations/8e6ecd60-8eb4-40cc-a985-2dfdb04c74be

> FDA guidance document: Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations. Issue date: June 23, 2022. Get complete insights and analysis.

---

## Details

- Title: Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-06-23
- Last Changed: 2024-04-12
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-4368">FDA-2018-D-4368</a>

## Related Documents

- [Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies/3a1b0e14-f87e-4c72-b198-baa24f196e9a)
- [Bioavailability Studies Submitted in NDAs or INDs – General Considerations](https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-studies-submitted-in-ndas-or-inds-general-considerations/8946e94a-0bb7-41ed-a95c-e1fed34bf86b)
- [Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/716f5680-73b2-4cf4-a88d-c5ade3c8aecd)